Differential Anti-S Antibody Titers in Vaccinated Residents During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 (β) in an Elderly Nursing Home

Fourati, Slim; Bailly, B.; Bouter, Anne Le; Guilpain, Luc; Rodriguez, Christophe; Pawlotsky, Jean‐Michel

doi:10.1093/cid/ciab676

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of November 2021, the World Health Organization (WHO) had reported over 250 million confirmed cases and more than 5 million deaths due to COVID-19 (1). SARS-CoV-2 Spike antibody inducing vaccines have dramatically slowed the infection and death rate in the developed world, however, breakthrough infections due to delta and other variant viruses continue, and infection rates continue to rise in non-vaccinated regions (2)(3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Lin

Law

Korosec

et al. 2022

Preprint

View full text Add to dashboard Cite

Cellular-mediated immunity is critical for long-term protection against most viral infections, including coronaviruses. We studied 23 SARS-CoV-2-infected survivors over a one year post symptom onset (PSO) interval by ex vivo cytokine ELISpot assay. All subjects demonstrated SARS-CoV-2-specific IFN-γ, IL-2, and Granzyme B (GzmB) T cell responses at presentation, with greater frequencies in severe disease. Cytokines, mainly produced by CD4+ T cells, targeted all structural proteins (Nucleocapsid, Membrane, Spike) except Envelope, with GzmB > IL-2 > IFN-γ. Mathematical modeling predicted that: 1) cytokine responses peaked at 6 days for IFN-γ, 36 days for IL-2, and 7 days for GzmB, 2) severe illness was associated with reduced IFN-γ and GzmB, but increased IL-2 production rates, 3) males displayed greater production of IFN-γ, whereas females produced more GzmB. Ex vivo responses declined over time with persistence of IL-2 in 86% and of IFN-γ and GzmB in 70% of subjects at a median of 336 days PSO. The average half-life of SARS-CoV-2-specific cytokine-producing cells was modelled to be 139 days (~4.6 months). Potent T cell proliferative responses persisted throughout observation, were CD4 dominant, and were capable of producing all 3 cytokines. Several immunodominant CD4 and CD8 epitopes identified in this study were shared by seasonal coronaviruses or SARS-CoV-1 in the Nucleocapsid and Membrane regions. Both SARS-CoV-2-specific CD4+ and CD8+ T cell clones were able to kill target cells, though CD8 tended to be more potent.

show abstract

Section: Introductionmentioning

confidence: 99%

Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Lin

Law

Korosec

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Aktuelles zur Grippeimpfung und COVID-19-Auffrischimpfung

Kwetkat¹,

Heppner²,

Endres³

et al. 2021

Geriatr Rep

View full text Add to dashboard Cite

Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Lin

Law

Korosec

et al. 2022

J Virol

View full text Add to dashboard Cite

Our findings highlight the relative importance of SARS-CoV-2-specific GzmB-producing T cell responses in SARS-CoV-2 control and shared CD4 and CD8 immunodominant epitopes in seasonal coronaviruses or SARS-CoV-1, and they indicate robust persistence of T cell memory at least 1 year after infection. Our findings should inform future strategies to induce T cell vaccines against SARS-CoV-2 and other coronaviruses.

show abstract

Differential Anti-S Antibody Titers in Vaccinated Residents During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 (β) in an Elderly Nursing Home

Cited by 3 publications

References 3 publications

Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Aktuelles zur Grippeimpfung und COVID-19-Auffrischimpfung

Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

Contact Info

Product

Resources

About